United States: FDA Issues Updated Draft Guidance On Reporting Drug Samples

Last Updated: August 7 2014
Article by Kathleen M. Sanzo and Rebecca Osowski

The guidance calls for 2014 reporting by April 1, 2015.

When signed into law in March 2010, the Affordable Care Act (ACA) put a renewed focus on transparency. While section 6002, the Physician Payment Sunshine Act, took center stage with broad tracking and reporting requirements related to payment or transfers of value made to physicians and teaching hospitals, section 6004 also took effect with significantly less fanfare.


At the most basic level, section 6004 requires manufacturers and distributors to submit annually to the Food and Drug Administration (FDA) certain data regarding drug samples requested and provided to licensed practitioners, including the identity and quantity.1 The requirements to maintain information related to the distribution of drug samples have long been in place under the Prescription Drug Marketing Act of 1987 (PDMA).2 PDMA includes the following:

  • Requirements for the distribution of drug samples to physicians and pharmacies of hospitals and other healthcare entities, including labeling requirements and the retention of a physician-signed request form for the sample, as well as acknowledgement of receipt upon delivery of the sample, both with specific information mandated (e.g., name, address, professional designation)
  • Requirements for manufacturers and distributors to review their inventory of drug samples, investigate discrepancies and any identified significant losses or thefts, and file appropriate reports with the FDA

To be eligible to receive a drug sample, a practitioner must be licensed to prescribe drugs within the state in which he or she practices.

On April 3, 2012—around the time that the ACA requirement to begin reporting data to the FDA became effective—the FDA issued "Draft Guidance for Industry on Compliance Policy for Reporting Drug Sample Distribution Information."3 This draft guidance communicated the availability of the FDA's Electronic Submission Gateway (the Gateway) as the system to use to report this information. The guidance also explained that the FDA intended to use enforcement discretion until at least October 1, 2012 for companies that had not submitted information under those reporting provisions. The FDA later announced that it expected to issue further guidance in 2013.4

The recent draft guidance document, "Guidance for Industry—Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act," was issued on July 11, 2014 and replaces the prior draft guidance.5 This new guidance better outlines the requirements to assist those individuals who use the Gateway to submit data. The FDA expects that companies will comply with section 6004 reporting requirements as set forth in the updated guidance, which is summarized below.

Reporting Requirements

Although manufacturers and authorized distributors of record (ADRs)6that dispense drug samples have long since implemented the compliance programs necessary to comply with PDMA requirements, the actual submission of this data to the FDA adds a layer of complexity to an already onerous process. The required data will now have to be maintained in a manner that can easily be transferred into the FDA-required format for electronic submission through the Gateway.

Data regarding the type and quantity of drug samples requested and distributed must now be submitted to the FDA. This information must be aggregated by individual name, address, and professional designation and must indicate that signature information is on file for the practitioner who makes the request and the practitioner or the practitioner's designee who receives the distributed drug sample. Key data elements or required fields will include the following:

  • The date of the transaction (i.e., the date of the request from the practitioner and the date the sample was distributed to the practitioner)
  • The trade name and dosage of the drug sample distributed (Trade Name A, 100 mg)
  • The sample package size, including the units per package (One bottle of 1,000)
  • The total quantity of the drug requested by the practitioner during the calendar year
  • The total quantity of the drug distributed to the practitioner during the calendar year
  • The name (first, last, and middle initial) of the practitioner
  • The professional designation of the practitioner (e.g., M.D., D.O.)
  • The address of the practitioner, including street number, street name, suite or room number, city, state, and zip code
  • A signature-on-file indicator to confirm that the practitioner actually signed the request for samples
  • A signature-on-file indicator to confirm that the practitioner or designee actually signed the acknowledgement of receipt upon delivery of the sample

Visit the FDA website to access the XML schema that shows the format for reporting this data through the Gateway.

Key Dates

The FDA expects manufacturers and ADRs to comply with section 6004 reporting requirements according to the policies set forth in the guidance, beginning with the submission of data for the calendar year 2014 due no later than April 1, 2015.

The FDA has offered a comment period for this guidance. Electronic or written comments on the draft guidance must be submitted by October 9, 2014, and comments concerning the proposed collection of information must be submitted by September 9, 2014.7

Other Considerations

The requirement to submit drug sample information under section 6004 of the ACA applies to each manufacturer and ADR of an applicable drug that makes sample distributions. Essentially, this means that both manufacturers and ADRs of applicable drugs have the authority to submit drug sample information to the FDA. However, the FDA requires that only one party submit the required drug sample information. The FDA believes that manufacturers are best positioned to determine who will do the reporting for their drug samples and advises manufacturers to ensure that ADR agreements specify who is responsible for reporting the required drug sample information to the FDA.

Requests and the distribution of drug samples should be reported for the year in which they occurred. The guidance indicates that the FDA recognizes that, as a consequence, the number of requests and deliveries may not be the same for a given reporting period. In other words, if a request is made in December 2014 and not distributed until January 2015, only the information related to the request would be submitted with the calendar year 2014 data.

In preparation for the upcoming data-submission deadline, manufacturers and ADRs should review current standard operating procedures and remodel as necessary to account for this new requirement. For example, while practitioner signatures are required for requests and delivery acknowledgement, internal processes regarding whether any data field within the system(s) used to track drug samples is populated to evidence the receipt of these signatures may need to be revisited and revised.

Additionally, some evaluation of current information technology capabilities may also be needed to ensure that all necessary data components are captured within the system and that the necessary data transfer can occur as required.


[1]. See 21 U.S.C. § 353(d)(2), (d)(3).

[2]. See 21 CFR pt. 203 subpart D.

[3]. Docket No. FDA-2012-D-0300.

[4]. Read the announcement here.

[5]. View the full text of the new draft guidance document here.

[6]. ADRs are defined within the updated guidance document as "distributors with whom a manufacturer has established an ongoing relationship to distribute such manufacturer's products."

[7]. Comments may be submitted here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.